AIM ImmunoTech (STU:HXB) Beta: -0.0268 (As of Jun. 27, 2026)


STU:HXB AIM ImmunoTech Inc STU:HXB
33 GF Score
Price €5.76
GF Value €49.66
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Beta?

AIM ImmunoTech STU:HXB 33 Beta is -0.0268 as of Jun. 27, 2026. GuruFocus rates STU:HXB with a GF Score™ of 33/100 and a GF Value™ of €49.66. The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), AIM ImmunoTech's Beta is -0.0268.


AIM ImmunoTech  (STU:HXB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


AIM ImmunoTech Beta Related Terms


AIM ImmunoTech Beta Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Beta Chart

AIM ImmunoTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.72 -1.56 1.01 1.09 1.46

AIM ImmunoTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.33 0.30 1.46 -0.23

STU:HXB vs BGMS, FBLG, CLGN: Beta Comparison

For the Biotechnology subindustry, AIM ImmunoTech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Beta distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Beta falls into.


STU:HXB
33GF Score
AIM ImmunoTech Inc STU:HXB
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.0268 mean?
AIM ImmunoTech (STU:HXB) has a Beta of -0.0268 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for AIM ImmunoTech and its competitors.
Is AIM ImmunoTech's Beta too high?
AIM ImmunoTech's current Beta is -0.0268. Overall, AIM ImmunoTech has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Beta compare to BGMS and FBLG?
AIM ImmunoTech's Beta of -0.0268 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for AIM ImmunoTech and its competitors. AIM ImmunoTech's current Beta is -0.0268. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
AIM ImmunoTech (STU:HXB) has a current Beta of -0.0268. The stock's GF Value™ is €49.66, compared to a current price of €5.76 — trading 88.4% below its estimated fair value. The current Beta is -0.0268. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For AIM ImmunoTech (STU:HXB), the current Beta is -0.0268 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (STU:HXB) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of €5.76 is trading 88.4% below its estimated GF Value™ of €49.66.

Key valuation signals for STU:HXB:

  • Beta: -0.0268
  • GF Value™: €49.66 vs. price of €5.76 (88.4% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the STU:HXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AIM ImmunoTech Business Description

Other Exchanges AIM:USA0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for STU:HXB

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.76
Price
€49.66
GF Value